The current financial score of Teva Pharmaceutical Industries Ltd is 7.41. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 4.15B, representing a year-over-year decrease of 1.38%, while its net profit experienced a year-over-year decrease of 304.26%.
The current valuation score of Teva Pharmaceutical Industries Ltd is 8.20. Its current P/E ratio is 32.53, which is 62.00% below the recent high of 52.70 and 637.34% above the recent low of -174.80.
The current earnings forecast score of Teva Pharmaceutical Industries Ltd is 8.67. The average price target is 33.00, with a high of 33.00 and a low of 33.00.
The current price momentum score of Teva Pharmaceutical Industries Ltd is 3.90. Currently, the stock price is trading between the resistance level at 42.09 and the support level at 36.72, making it suitable for range-bound swing trading.
The current institutional shareholding score of Teva Pharmaceutical Industries Ltd is 5.00. The latest institutional shareholding proportion is 62.27%, representing a quarter-over-quarter increase of 7.66%.
The current risk assessment score of Teva Pharmaceutical Industries Ltd is 8.24. The company's beta value is 0.81. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.